慢性阻塞性肺疾病患者多重用药现况及管理策略_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

陈丽华 ¹ , 宋怡 ^1,2 , 何权瀛 ³ ,  莫莉 ¹

1. ;
2. ;
3. ;

Corresponding author：

莫莉, Email: molleyhe@hotmail.com

Keywords：

DOI：

10.7507/1671-6205.202103030

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 陈丽华, 宋怡, 何权瀛, 莫莉. 慢性阻塞性肺疾病患者多重用药现况及管理策略. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(5): 362-365. doi: 10.7507/1671-6205.202103030 Copy

1.	Chetty U, McLean G, Morrison D, et al. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract, 2017, 67(658): e321-e328.
2.	Hanlon P, Nicholl BI, Jani BD, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open, 2018, 8(1): e018404.
3.	Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med, 2015, 3(8): 631-639.
4.	Cebron Lipovec N, Beijers RJ, van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD, 2016, 13(3): 399-406.
5.	Global Initiative for Chronic Obstructive Lung Disease Inc. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2020 report[EB/OL]. [2020-12-30]. Available from: https://www.goldcopd.org.
6.	Fumagalli G, Fabiani F, Forte S, et al. INDACO project: COPD and link between comorbidities, lung function and inhalation therapy. Multidiscip Respir Med, 2015, 10(1): 4.
7.	Sirois C, Ouali A, Simard M. Polypharmacy among older individuals with COPD: trends between 2000 and 2015 in Quebec, Canada. COPD, 2019, 16(3-4): 234-239.
8.	Poudel A, Peel NM, Nissen LM, et al. Adverse outcomes in relation to polypharmacy in robust and frail older hospital patients. J Am Med Dir Assoc, 2016, 17(8): 767, e9-e13.
9.	Mo L, Yang X, He J, et al. Evaluation of potentially inappropriate medications in older inpatients in China. J Am Geriatr Soc, 2014, 62(11): 2216-2218.
10.	Rochon PA. Drug prescribing for older adults[EB/OL]. [2020-12-30]. Available from: https://www.uptodate.com/.
11.	Savaria F, Beauchesne MF, Forget A, et al. Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics. Respir Med, 2017, 132: 195-202.
12.	Diez-Manglano J, Barquero-Romero J, Mena PA, et al. Polypharmacy in patients hospitalised for acute exacerbation of COPD. Eur Respir J, 2014, 44(3): 791-794.
13.	Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med, 2011, 22(6): 597-602.
14.	Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2011, 6: 493-501.
15.	Reilly JJ. Stepping down therapy in COPD. N Engl J Med, 2014, 371(14): 1340-1341.
16.	Anecchino C, Rossi E, Fanizza C, et al. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis, 2007, 2(4): 567-574.
17.	Roblek T, Trobec K, Mrhar A, et al. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci, 2014, 10(5): 920-932.
18.	Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 2004, 329(7456): 15-19.
19.	Vonbach P, Dubied A, Krahenbuhl S, et al. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med, 2008, 19(6): 413-420.
20.	Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med, 2015, 13: 74.
21.	Ajmera M, Shen C, Sambamoorthi U. Concomitant medication use and new-onset diabetes among medicaid beneficiaries with chronic obstructive pulmonary disease. Popul Health Manag, 2017, 20(3): 224-232.
22.	Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med, 2010, 123(11): 1001-1006.
23.	Bender BG. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should we do next?. Curr Opin Pulm Med, 2014, 20(2): 132-137.
24.	Davis E, Marra C, Gamble JM, et al. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials, 2016, 17(1): 502.
25.	Shrestha R, Pant A, Shakya Shrestha S, et al. A cross-sectional study of medication adherence pattern and factors affecting the adherence in chronic obstructive pulmonary disease. Kathmandu Univ Med J (KUMJ), 2015, 13(49): 64-70.
26.	Vetrano DL, Bianchini E, Onder G, et al. Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacy. Geriatr Gerontol Int, 2017, 17(12): 2500-2506.
27.	Huetsch JC, Uman JE, Udris EM, et al. Predictors of adherence to inhaled medications among Veterans with COPD. J Gen Intern Med, 2012, 27(11): 1506-1512.
28.	Cecere LM, Slatore CG, Uman JE, et al. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). COPD, 2012, 9(3): 251-258.
29.	刘晓红, 陈彪, 主编. 老年医学. 第 1 版. 北京: 人民卫生出版社, 2020, 47-54.
30.	By the American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 2019, 67(4): 674-694.
31.	O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing, 2015, 44(2): 213-218.
32.	丁玎, 莫莉. 关注老年人合理用药. 实用老年医学, 2016, 30(6): 443-447.
33.	Dalton K, O'Brien G, O'Mahony D, et al. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing, 2018, 47(5): 670-678.
34.	Adam L, Moutzouri E, Baumgartner C, et al. Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open, 2019, 9(6): e026769.
35.	Lavan AH, O'Mahony D, Gallagher P, et al. The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort -Trial Protocol. BMC Geriatr, 2019, 19(1): 40.
36.	Poh EW, McArthur A, Stephenson M, et al. Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. JBI Database System Rev Implement Rep, 2018, 16(9): 1823-1873.
37.	Kruis AL, Soljak M, Chavannes NH, et al. COPD Multidisciplinary Team Meetings in the United Kingdom: Health Care Professionals' Perceptions of Aims and Structure. COPD, 2016, 13(5): 639-641.
38.	刘颖, 宋怡, 丁玎, 等. 临床医生对老年人合理用药继续医学教育需求的现况调查. 甘肃医药, 2020, 39(7): 125-130, 113.
39.	Lavan AH, Gallagher PF, O'Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging, 2016, 11: 857-866.

1. Chetty U, McLean G, Morrison D, et al. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract, 2017, 67(658): e321-e328.
2. Hanlon P, Nicholl BI, Jani BD, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open, 2018, 8(1): e018404.
3. Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med, 2015, 3(8): 631-639.
4. Cebron Lipovec N, Beijers RJ, van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD, 2016, 13(3): 399-406.
5. Global Initiative for Chronic Obstructive Lung Disease Inc. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2020 report[EB/OL]. [2020-12-30]. Available from: https://www.goldcopd.org.
6. Fumagalli G, Fabiani F, Forte S, et al. INDACO project: COPD and link between comorbidities, lung function and inhalation therapy. Multidiscip Respir Med, 2015, 10(1): 4.
7. Sirois C, Ouali A, Simard M. Polypharmacy among older individuals with COPD: trends between 2000 and 2015 in Quebec, Canada. COPD, 2019, 16(3-4): 234-239.
8. Poudel A, Peel NM, Nissen LM, et al. Adverse outcomes in relation to polypharmacy in robust and frail older hospital patients. J Am Med Dir Assoc, 2016, 17(8): 767, e9-e13.
9. Mo L, Yang X, He J, et al. Evaluation of potentially inappropriate medications in older inpatients in China. J Am Geriatr Soc, 2014, 62(11): 2216-2218.
10. Rochon PA. Drug prescribing for older adults[EB/OL]. [2020-12-30]. Available from: https://www.uptodate.com/.
11. Savaria F, Beauchesne MF, Forget A, et al. Polypharmacy, chronic kidney disease, and benign prostatic hyperplasia in patients with chronic obstructive pulmonary disease newly treated with long-acting anticholinergics. Respir Med, 2017, 132: 195-202.
12. Diez-Manglano J, Barquero-Romero J, Mena PA, et al. Polypharmacy in patients hospitalised for acute exacerbation of COPD. Eur Respir J, 2014, 44(3): 791-794.
13. Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med, 2011, 22(6): 597-602.
14. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2011, 6: 493-501.
15. Reilly JJ. Stepping down therapy in COPD. N Engl J Med, 2014, 371(14): 1340-1341.
16. Anecchino C, Rossi E, Fanizza C, et al. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis, 2007, 2(4): 567-574.
17. Roblek T, Trobec K, Mrhar A, et al. Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci, 2014, 10(5): 920-932.
18. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 2004, 329(7456): 15-19.
19. Vonbach P, Dubied A, Krahenbuhl S, et al. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med, 2008, 19(6): 413-420.
20. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med, 2015, 13: 74.
21. Ajmera M, Shen C, Sambamoorthi U. Concomitant medication use and new-onset diabetes among medicaid beneficiaries with chronic obstructive pulmonary disease. Popul Health Manag, 2017, 20(3): 224-232.
22. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med, 2010, 123(11): 1001-1006.
23. Bender BG. Nonadherence in chronic obstructive pulmonary disease patients: what do we know and what should we do next?. Curr Opin Pulm Med, 2014, 20(2): 132-137.
24. Davis E, Marra C, Gamble JM, et al. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials, 2016, 17(1): 502.
25. Shrestha R, Pant A, Shakya Shrestha S, et al. A cross-sectional study of medication adherence pattern and factors affecting the adherence in chronic obstructive pulmonary disease. Kathmandu Univ Med J (KUMJ), 2015, 13(49): 64-70.
26. Vetrano DL, Bianchini E, Onder G, et al. Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacy. Geriatr Gerontol Int, 2017, 17(12): 2500-2506.
27. Huetsch JC, Uman JE, Udris EM, et al. Predictors of adherence to inhaled medications among Veterans with COPD. J Gen Intern Med, 2012, 27(11): 1506-1512.
28. Cecere LM, Slatore CG, Uman JE, et al. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD). COPD, 2012, 9(3): 251-258.
29. 刘晓红, 陈彪, 主编. 老年医学. 第 1 版. 北京: 人民卫生出版社, 2020, 47-54.
30. By the American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 2019, 67(4): 674-694.
31. O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing, 2015, 44(2): 213-218.
32. 丁玎, 莫莉. 关注老年人合理用药. 实用老年医学, 2016, 30(6): 443-447.
33. Dalton K, O'Brien G, O'Mahony D, et al. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing, 2018, 47(5): 670-678.
34. Adam L, Moutzouri E, Baumgartner C, et al. Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. BMJ Open, 2019, 9(6): e026769.
35. Lavan AH, O'Mahony D, Gallagher P, et al. The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort -Trial Protocol. BMC Geriatr, 2019, 19(1): 40.
36. Poh EW, McArthur A, Stephenson M, et al. Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review. JBI Database System Rev Implement Rep, 2018, 16(9): 1823-1873.
37. Kruis AL, Soljak M, Chavannes NH, et al. COPD Multidisciplinary Team Meetings in the United Kingdom: Health Care Professionals' Perceptions of Aims and Structure. COPD, 2016, 13(5): 639-641.
38. 刘颖, 宋怡, 丁玎, 等. 临床医生对老年人合理用药继续医学教育需求的现况调查. 甘肃医药, 2020, 39(7): 125-130, 113.
39. Lavan AH, Gallagher PF, O'Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging, 2016, 11: 857-866.

Previous Article
以左肺上叶不张为临床表现的肺软骨瘤合并肺鳞癌一例
Next Article
氢化可的松、维生素 C 和维生素 B1 联合治疗脓毒症研究进展

Chinese Journal of Respiratory and Critical Care Medicine

慢性阻塞性肺疾病患者多重用药现况及管理策略

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content